2 weeks Ago By Defense World Staff
Belite Bio, Inc ( NASDAQ:BLTE – Get Free Report )’s share price reached a new 52-week high on Thursday after HC Wainwright raised their price target on the stock from $60.00 to $100.00.
HC Wainwright currently has a buy rating on the stock. Belite Bio traded as high as $86.20 and last traded at $86.
20, with a volume of 59231 shares. The stock had previously closed at $82.23.
Separately, Benchmark reiterated a “buy” rating and issued a $57.00 price objective on shares of Belite Bio in a research report on Tuesday, August 13th. Get Our Latest Stock Report on BLTE Institutional Inflows and Outflows Belite Bio Trading Up 1.
7 % The stock’s fifty day moving average price is $58.53 and its 200 day moving average price is $51.23.
The stock has a market cap of $2.56 billion, a P/E ratio of -75.37 and a beta of -1.
60. Belite Bio ( NASDAQ:BLTE – Get Free Report ) last released its earnings results on Tuesday, November 12th. The company reported ($0.
28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02.
During the same period in the prior year, the firm posted ($0.40) earnings per share. On average, analysts anticipate that Belite Bio, Inc will post -1.
19 earnings per share for the current year. Belite Bio Company Profile ( Get Free Report ) Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
See Also Five stocks we like better than Belite Bio What is a Low P/E Ratio and What Does it Tell Investors? 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours? Mouse Rising: The Iger Investment Pays Off for Disney Investors Stock Dividend Cuts Happen Are You Ready? Can CAVA Stock Be the Next Chipotle? Earnings Can Help Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter .
.
